EA030646B1 - Соединения и способы их применения - Google Patents

Соединения и способы их применения Download PDF

Info

Publication number
EA030646B1
EA030646B1 EA201590987A EA201590987A EA030646B1 EA 030646 B1 EA030646 B1 EA 030646B1 EA 201590987 A EA201590987 A EA 201590987A EA 201590987 A EA201590987 A EA 201590987A EA 030646 B1 EA030646 B1 EA 030646B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
bis
diyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EA201590987A
Other languages
English (en)
Russian (ru)
Other versions
EA201590987A1 (ru
Inventor
Рене М. Лемье
Джанета Поповичи-Мюллер
Франческо Г. Салитуро
Джеффри О. Сондерз
Джереми М. Трэвинс
Юншэн Чэнь
Original Assignee
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аджиос Фармасьютикалз, Инк. filed Critical Аджиос Фармасьютикалз, Инк.
Publication of EA201590987A1 publication Critical patent/EA201590987A1/ru
Publication of EA030646B1 publication Critical patent/EA030646B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201590987A 2012-11-22 2013-11-21 Соединения и способы их применения EA030646B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (2)

Publication Number Publication Date
EA201590987A1 EA201590987A1 (ru) 2015-12-30
EA030646B1 true EA030646B1 (ru) 2018-09-28

Family

ID=50775393

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590987A EA030646B1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения
EA201890754A EA201890754A1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890754A EA201890754A1 (ru) 2012-11-22 2013-11-21 Соединения и способы их применения

Country Status (36)

Country Link
US (2) US10087172B2 (enExample)
EP (2) EP3456719A1 (enExample)
JP (2) JP6333277B2 (enExample)
KR (1) KR20150085079A (enExample)
CN (2) CN108727307A (enExample)
AR (1) AR093598A1 (enExample)
AU (2) AU2013347771B2 (enExample)
BR (1) BR112015011830A2 (enExample)
CA (1) CA2893510C (enExample)
CL (1) CL2015001392A1 (enExample)
CR (1) CR20150316A (enExample)
CY (1) CY1120581T1 (enExample)
DK (1) DK2922850T3 (enExample)
EA (2) EA030646B1 (enExample)
EC (1) ECSP15026557A (enExample)
ES (1) ES2690390T3 (enExample)
HR (1) HRP20181628T1 (enExample)
HU (1) HUE040111T2 (enExample)
IL (1) IL238958B (enExample)
LT (1) LT2922850T (enExample)
MX (1) MX367389B (enExample)
MY (1) MY177344A (enExample)
NZ (1) NZ708382A (enExample)
PE (1) PE20151072A1 (enExample)
PH (2) PH12015501150B1 (enExample)
PL (1) PL2922850T3 (enExample)
PT (1) PT2922850T (enExample)
RS (1) RS57859B1 (enExample)
SA (1) SA515360469B1 (enExample)
SG (2) SG10201609940RA (enExample)
SI (1) SI2922850T1 (enExample)
SM (1) SMT201800504T1 (enExample)
TR (1) TR201812360T4 (enExample)
TW (2) TW201906825A (enExample)
UA (1) UA117360C2 (enExample)
WO (3) WO2014079011A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
JP6275153B2 (ja) 2012-11-16 2018-02-07 キャリセラ バイオサイエンシーズ, インコーポレイテッド ヘテロ環式グルタミナーゼ阻害剤
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CA2892817A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
MX2016012244A (es) * 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.
MX2016014143A (es) * 2014-04-30 2017-02-15 Pfizer Derivados de diheterociclo enlazado a cicloalquilo.
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学系统董事会 用于治疗疾病的gls1抑制剂
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
WO2016054388A1 (en) * 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10441587B2 (en) 2015-04-06 2019-10-15 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017062354A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
US10150753B2 (en) 2015-12-22 2018-12-11 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2018039544A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP7361687B2 (ja) 2017-10-18 2023-10-16 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム グルタミナーゼ阻害薬療法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
DE69425882T2 (de) 1993-03-29 2001-01-11 Basf Ag 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
AU2008326497B2 (en) 2007-11-19 2014-02-13 Genentech, Inc. Compositions and methods for inhibiting tumor progression
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
JP2012524280A (ja) 2009-04-17 2012-10-11 オーエスアイ・ファーマシューティカルズ,エルエルシー 上皮成長因子受容体キナーゼ阻害剤に対する抗がん反応を予測するための生物学的マーカー
WO2011143160A2 (en) * 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20130109592A1 (en) 2010-06-23 2013-05-02 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
RU2014141114A (ru) 2012-03-15 2016-05-10 Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US20160008380A1 (en) 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
MX2016012244A (es) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kumar, Parvin. Synthesis and pharmacological evaluation of some novel imidazo[2,1-b][1,3,4]thiadiazole derivatives. Chinese Journal of Chemistry, 2010, Vol. 28, No. 2, pages 250-254 *
Panwar, Hemant et al., Studies on some bioactive 1,1-bis(2-benzylidene-5-arylidene-1,3-thiadiazolidin-4-one)cyclopropane. Journal of the Korean Chemical Society, 2011, Vol. 55, No. 6, pages 994-999 *

Also Published As

Publication number Publication date
JP6333277B2 (ja) 2018-05-30
CY1120581T1 (el) 2019-07-10
US10087172B2 (en) 2018-10-02
CN104936954B (zh) 2018-08-14
HK1214593A1 (en) 2016-07-29
TW201906825A (zh) 2019-02-16
EP2922850A4 (en) 2016-05-18
PT2922850T (pt) 2018-10-15
BR112015011830A2 (pt) 2017-07-11
WO2014079150A1 (en) 2014-05-30
TR201812360T4 (tr) 2018-09-21
IL238958A0 (en) 2015-07-30
US20150291576A1 (en) 2015-10-15
HRP20181628T1 (hr) 2018-12-14
PH12017502141A1 (en) 2019-02-27
WO2014079136A1 (en) 2014-05-30
NZ708382A (en) 2020-04-24
SI2922850T1 (sl) 2018-10-30
AU2018202954A1 (en) 2018-05-17
ES2690390T3 (es) 2018-11-20
CR20150316A (es) 2015-08-28
CA2893510C (en) 2021-01-19
SG10201609940RA (en) 2016-12-29
IL238958B (en) 2019-09-26
MY177344A (en) 2020-09-13
MX367389B (es) 2019-08-19
SA515360469B1 (ar) 2017-07-11
UA117360C2 (uk) 2018-07-25
SG11201504049VA (en) 2015-07-30
US10689375B2 (en) 2020-06-23
EA201590987A1 (ru) 2015-12-30
EP2922850B1 (en) 2018-07-18
TWI629268B (zh) 2018-07-11
JP2018150316A (ja) 2018-09-27
EA201890754A1 (ru) 2018-08-31
PH12015501150B1 (en) 2018-05-04
AR093598A1 (es) 2015-06-10
CL2015001392A1 (es) 2016-04-22
US20190084976A1 (en) 2019-03-21
RS57859B1 (sr) 2018-12-31
AU2013347771A1 (en) 2015-06-11
AU2013347771B2 (en) 2018-02-01
JP2016500082A (ja) 2016-01-07
DK2922850T3 (en) 2018-10-08
HUE040111T2 (hu) 2019-02-28
CN104936954A (zh) 2015-09-23
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
PE20151072A1 (es) 2015-08-26
EP3456719A1 (en) 2019-03-20
SMT201800504T1 (it) 2018-11-09
TW201427963A (zh) 2014-07-16
ECSP15026557A (es) 2016-01-29
PL2922850T3 (pl) 2018-12-31
LT2922850T (lt) 2018-09-10
EP2922850A1 (en) 2015-09-30
WO2014079011A1 (en) 2014-05-30
PH12015501150A1 (en) 2015-08-17
CN108727307A (zh) 2018-11-02
CA2893510A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
EA030646B1 (ru) Соединения и способы их применения
AU2013347933B2 (en) Glutamase inhibitors and method of use
US20140142081A1 (en) Compounds and their methods of use
RU2769327C2 (ru) Модуляторы интегрированного сигнального пути стресса
US9434734B2 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
BRPI0608205B1 (pt) derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor
BR112016025248B1 (pt) Compostos inibidores de demetilase lisina-específica-1, composição farmacêutica e seus usos
JP2013503190A (ja) Raf阻害化合物およびその使用方法
JP2019534857A (ja) 神経保護作用、自己免疫性ならびに癌の疾患および病状において有用な1,2−ジチオラン化合物
JP2021527044A (ja) 統合的ストレス応答経路の阻害剤
KR20080072688A (ko) 옥사디아졸 유도체
CN106231900A (zh) 化合物及其使用方法
US20190152979A1 (en) Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
US10106518B2 (en) Chromene derivatives as inhibitors of TCR-Nck interaction
HK1214593B (en) Compounds and their methods of use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU